Effects of testosterone on bone turnover markers in transgender male.
- Conditions
- Adults diagnosed with gender dysphoria (based on DSM V) by psychiatristAge 20 to 40 years oldNever used cross-sex hormone therapytransgender, transmale, cross-sex hormone
- Registration Number
- TCTR20220817002
- Lead Sponsor
- King Chulalongkorn Memorial Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- nknown
- Sex
- Female
- Target Recruitment
- 22
Inclusion Criteria
Adults diagnosed with gender dysphoria (based on DSM V) by psychiatrist
Age 20 to 40 years old
Never used cross-sex hormone therapy
Exclusion Criteria
Underlying disease (Cardiovascular, stroke, VTE, DLP, OSA)
Endometrial cancer, breast cancer
HIV infections
Bone metastasis, pathological fracture
Impaired renal function (GFR<15)
Parathyroid, thyroid abnormalities
Anti-osteoporotic drugs (bisphosphonate, denosumab, teriparatide, SERMs)
Hormonal drug use (aromatase inhibitor, OCPs)
Corticosteroid use
Anti-epileptic drugs (phenytoin, phenobarbital,carbamazepine)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes of bone resorption markers (CTX) after 3 months of testosterone treatment 3 months different between pre and post treatment
- Secondary Outcome Measures
Name Time Method Changes of bone turnover markers ( P1NP, osteocalcin) after 6 months of testosterone treatment 6 months different between pre and post treatment,Correlation of sex hormone levels with bone turnover marker levels. 6 months different between pre and post treatment